Although the role of inflammation in atherosclerosis has been identified over 150 years ago by Virchow (63), only recently has the “inflammation hypothesis” in atherosclerosis been specifically tested with an anti-inflammatory drug targeting IL-1β. Here, IL1B is linked to atherosclerosis.